White blood cell count nadir following remission induction chemotherapy is predictive of outcome in older adults with acute myeloid leukemia

References

• Ries L AG, Melbert D, Krapcho M, Mariotto A, Miller B A, Feuer E J, et al. SEER Cancer Statistics Review, 1975 – 2004. National Cancer Institute, Bethesda, Maryland 2007
   Google Scholar
• Sekeres M A, Stone R M, Zahrieh D, Neuberg D, Morrison V, De Angelo D J, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004; 18: 809–816
   PubMed Web of Science ®Google Scholar
• Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison C J, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98: 1312–1320
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006; 106: 1090–1098
   PubMed Web of Science ®Google Scholar
• Mayer R J, Davis R B, Schiffer C A, Berg D T, Powell B L, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Stone R M, Berg D T, George S L, Dodge R K, Paciucci P A, Schulman P, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671–1677
   PubMed Web of Science ®Google Scholar
• Anderson J E, Kopecky K J, Willman C L, Head D, O'Donnell M R, Luthardt F W, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100: 3869–3876
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Suciu S, Archimbaud E, Haak H, Stryckmans P, de Cataldo R, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy – the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16: 872–881
   PubMed Web of Science ®Google Scholar
• Bauduer F, Ducout L, Dastugue N, Capdupuy C, Renoux M. De novo and secondary acute myeloid leukemia in patients over the age of 65: a review of fifty-six successive and unselected cases from a general hospital. Leuk Lymphoma 1999; 35: 289–296
   PubMed Web of Science ®Google Scholar
• Hoyle C F, de Bastos M, Wheatley K, Sherrington P D, Fischer P J, Rees J K, et al. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial. Br J Haematol 1989; 72: 45–53
   PubMed Web of Science ®Google Scholar
• Dillman R O, Davis R B, Green M R, Weiss R B, Gottlieb A J, Caplan S, et al. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood 1991; 78: 2520–2526
   PubMed Web of Science ®Google Scholar
• Rees J K, Gray R G, Swirsky D, Hayhoe F G. Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 1986; 2: 1236–1241
   PubMed Web of Science ®Google Scholar
• Leith C P, Kopecky K J, Godwin J, McConnell T, Slovak M L, Chen I M, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997; 89: 3323–3329
   PubMed Web of Science ®Google Scholar
• Estey E H. How I treat older patients with AML. Blood 2000; 96: 1670–1673
   PubMed Web of Science ®Google Scholar
• Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275–287
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003; 101: 64–70
   PubMed Web of Science ®Google Scholar
• Gajjar A, Ribeiro R, Hancock M L, Rivera G K, Mahmoud H, Sandlund J T, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292–1295
   PubMed Web of Science ®Google Scholar
• Griffin T C, Shuster J J, Buchanan G R, Murphy S B, Camitta B M, Amylon M D. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia 2000; 14: 792–795
   PubMed Web of Science ®Google Scholar
• Rubin E H, Andersen J W, Berg D T, Schiffer C A, Mayer R J, Stone R M. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia. J Clin Oncol 1992; 10: 948–953
   PubMed Web of Science ®Google Scholar
• Byrd J C, Mrozek K, Dodge R K, Carroll A J, Edwards C G, Arthur D C, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–4336
   PubMed Web of Science ®Google Scholar
• Bennett J M, Catovsky D, Daniel M T, Flandrin G, Galton D A, Gralnick H R, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–625
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Diebold J, Flandrin G, Muller-Hermelink H K, Vardiman J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419–1432
   PubMed Web of Science ®Google Scholar
• Nakul-Aquaronne D, Sudaka-Sammarcelli I, Ferrero-Vacher C, Starck B, Bayle J. Evaluation of the Sysmex Xe-2100 hematology analyzer in hospital use. J Clin Lab Anal 2003; 17(4)113–123
   PubMed Web of Science ®Google Scholar
• Herklotz R, Huber A R. Precision and accuracy of the leukocyte differential on the Sysmex XE-2100. Sysmex J Int 2001; 11: 8–21
   Google Scholar
• Cheson B D, Bennett J M, Kopecky K J, Buchner T, Willman C L, Estey E H, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003; 21: 4642–4649
   PubMed Web of Science ®Google Scholar
• Zhang H, Singer B. Recursive Partitioning in the Health Sciences. Springer-Verlag, New York 1999
   Google Scholar
• Pepe M S, Mori M. Kaplan-Meier, marginal or conditional probability curves in summarizing competing risks failure time data?. Stat Med 1993; 12: 737–751
   PubMed Web of Science ®Google Scholar
• Appelbaum F R, Gundacker H, Head D R, Slovak M L, Willman C L, Godwin J E, et al. Age and acute myeloid leukemia. Blood 2006; 107: 3481–3485
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Berdel W, Wormann B, Schoch C, Loffler H, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol 2002; 6: 46–59, discussion 86 – 87
   PubMedGoogle Scholar
• Wilson W H, Grossbard M L, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99: 2685–2693
   PubMed Web of Science ®Google Scholar